Narita Y, Nagane M, Mishima K, Terui Y, et al. Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro Oncol 2021;23:122-133.
PMID: 32583848